This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.

Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies.

This volume provides detailed descriptions of prevailing and novel techniques used by experts in the study of PTEN function in disease and biology. The book begins with chapters exploring methods to detect expression levels of PTEN in normal and diseased human specimens; methods to evaluate specific PTEN function in brain cancer; methods that utilize a new biosensor to measure PTEN regulation; and techniques to measure post-transcriptional regulation of PTEN by micoRNAs and ceRNAs. Other chapters present methods describing novel techniques to detect PTEN localization and previously unstudied structural features of PTEN measured through X-Ray Crystallography and Hydrogen Deuterium Exchange Mass Spectrometry. The book concludes with methods to study PTEN function in model organisms including mice and C. elegans. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and thorough, PTEN: Methods and Protocols is a valuable collection of methodologies and protocols useful to researchers who are interested in the PTEN field.

This volume will describe recent progress and future directions in radiation oncology and biology research, focusing on strategies designed to improve disease control and reduce the risk of long-term adverse effects on patients. As more and more patients are becoming long-term survivors, this strategy will become increasingly important--in radiation oncology and throughout the field of oncology.

This issue of Radiologic Clinics of North America focuses on Extranodal Lymphoma from Head to Toe, and is edited by Dr. Mark Murphey. Articles will include: Pathology of Extranodal Lymphoma; Pulmonary and Mediastinal Extranodal Lymphoma; Gastrointestinal Extranodal Lymphoma; Extranodal Lymphoma Involving the CNS and Spine; Genitourinary Extranodal Lymphoma; Musculoskeletal Extranodal Lymphoma; Pediatric Extranodal Lymphoma; Extranodal Lymphoma of the Breast; Cardiac Extranodal Lymphoma, and more!

After nearly three decades of providing medical care for women and men facing breast cancer, surgeon S. David Nathanson calls the survival rates today an ordinary miracle. Ordinary because the vast majority of patients now do live at least 20 years after diagnosis due to enormous progress that has been made in medicine; and a miracle too because of the intangible qualities such as faith and hope that seem key to success in battling the disease. In this book, survivors describe their experiences, emotions, and means to overcome the disease. S. David Nathanson is an esteemed, longtime surgeon who calls the survival rates today for women and men facing breast cancer nothing short of an ordinary miracle. Ordinary because the vast majority of patients live at least two decades after diagnosis, due to great advances that have been made in early detection, surgery, radiation, and chemotherapy. But also a miracle because we know that key elements for a woman or man succeeding in a personal battle against breast cancer include completely intangible qualities of courage, fortitude, trust, persistence, faith, and hope. Although science cannot completely explain it, a supportive network of family and friends with those qualities also empower patient survival and recovery. In these pages, Nathanson shares stories from his patients, teaching us about the experience of breast cancer and explaining how they found and fueled the will and power to defeat the disease. Even surgeon Nathanson himself cannot fully describe what goes through the hearts and minds of breast cancer patients as they discover, deal with, and finally triumph over the diagnosis. So in this book he acts as a narrator, letting his ordinary yet miraculous cancer survivors tell their stories, certainly filled with fear of the known and unknown, and with pain, but opening up to courage, love, sometimes humor, and finally hope. It is hope that firms up their resilience; hope that initiates their fortitude. Hope is an important component of healing, says the surgeon. Seventy-one survivors, including one man, tell their stories to ilustrate every step of the experience.

This book approaches the differential diagnosis and management of rare, hereditary cancer syndromes from a practical angle, addressing the issues pertinent to each tumour type as encountered by health professionals in their day-to-day practice. This book enables readers to correctly identify patients with rare cancer syndromes who would benefit from genetic counselling and testing, and provides the necessary knowledge for appropriate patient management and advising at-risk family members. It begins by describing recent advances in genetic testing for cancer-predisposing genes. Leading experts from Europe and Australia then offer detailed, up-to-date guidance on the diagnosis and management of a wide range of hereditary cancers. The concluding chapter examines the wider issues that are raised by genetic testing for rare cancer syndromes for patients, families and health professionals. This book is an invaluable source of information for all specialists involved in the care of such patients and their families.

The complexity of cancer demands an integrated approach from both a cancer biology standpoint and a pharmaceutical basis to understand the different anticancer modalities. Current research has been focused on conventional and newer anticancer modalities, recent discoveries in cancer research, and also the advancements in cancer treatment. There is a current need for more research on the advances in cancer therapeutics that bridge the gap between basic research (pharmaceutical drug development processes, regulatory issues, and translational experimentation) and clinical application. Recent promising discoveries such as immunotherapies, promising therapies undergoing clinical trials, synthetic lethality, carbon beam radiation, and other exciting targeted therapies are being studied to improve and advance the studies of modern cancer treatment. The Handbook of Research on Advancements in Cancer Therapeutics serves as a comprehensive guide in modern cancer treatment by combining and merging the knowledge from both cancer biology and the pharmacology of anticancer modalities. The chapters come from multi-disciplinary backgrounds, including scientists and clinicians from both academia and various industries, to discuss nascent personalized therapies and big data-driven cancer treatment. While highlighting topic areas that include cancer prevention, cancer therapeutics, and cancer treatments through the lenses of technology, medicine/drugs, and alternate therapies, this book is ideally intended for oncologists, radiation oncologists, surgical oncologists, and cancer biologists, along with practitioners, stakeholders, researchers, academicians, and students who are interested in understanding the most fundamental aspects of cancer and the available therapeutic opportunities.

This issue of Surgical Clinics of North America, guest edited by Dr. Clifford Cho, is devoted to Technical Aspects of Oncological Hepatic Surgery. He has assembled expert authors to review the following topics: Determination of Resectability; Radiographic Characterization of Hepatic Tumors; Chemotherapy-associated Hepatotoxicity; Preoperative Assessment and Optimization of the Future Liver Remnant; Anatomy of Hepatic Resectional Surgery; Resection of Gallbladder Carcinoma; Resection of Hilar Cholangiocarcinoma; Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular Carcinoma; Hemostasis and Hepatic Surgery; Minimally Invasive Hepatic Surgery; Hepatic Tumor Ablation; Hepatic Transarterial Therapies; Hepatic Perfusion Therapy; Hepatic Artery Infusional Chemotherapy; Ex vivo Hepatic Surgery, and more!

The study of the molecular events leading to cellular transformation and cancer has progressed significantly in the last decade, and it has become apparent that many genes subject to modification in cancer are, in fact, transcription factors that govern the execution of the genetic programme of the cell. Transcription factors can behave either as oncogenes or as tumour suppressor genes. To date only a limited number of transcription factors have been associated with cancer. This volume deals with several transcription factor families that were first identified in oncogenic retroviruses. Each chapter contains a description of the structure of the transcription factors, the nature of target genes, the regulation of their activities, and an explaination of how they can deregulate cell growth and differentiation. This text should be suitable for the specialist scientist and the advanced student

This book describes in detail current best practice in the diagnosis and treatment of malignant pediatric bone tumors and also discusses other important aspects of management. Clinical assessment, the role of different imaging modalities and choice of biopsy procedure are explained and an individual chapter is devoted to diagnostic pathology. The treatment-oriented chapters offer in-depth descriptions of chemotherapeutic regimens, radiation therapy, limb-salvage options and amputation-related issues and in addition consider the approach to lung nodules, the role of biomarkers, off-therapy monitoring and the treatment of relapse. Psychosocial impacts and needs are addressed and guidance provided on nursing during treatment and rehabilitation following orthopaedic surgery. Closing chapters evaluate emerging therapies and discuss disparate aspects of survivorship. The authors are acknowledged experts and include many contributors from the Nationwide Children's Hospital, a leading pediatric care facility in the United States.

This issue of Surgical Oncology Clinics of North America, guest edited by Nipun Merchant, MD, is devoted to Pancreatic Neoplasms. Dr. Merchant has assembled expert authors to review the following topics: Molecular and Genetic Basis of Pancreatic Carcinogenesis: Which Concepts May Be Clinically Relevant?; Role Of EUS and ERCP In The Clinical Assessment Of Pancreatic Neoplasms; Optimal Imaging Modalities For The Diagnosis and Staging Of Periampullary Lesions; Advances in the Surgical Management of Resectable and Borderline Resectable Pancreatic Cancer; Minimally Invasive Approaches to Pancreatic Surgery; Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer; Palliative Management of Unresectable Pancreatic Cancer; Spectrum and Classification of Cystic Lesions of the Pancreas; Therapeutic Approach to Cystic Neoplasms of the Pancreas; Clinical Presentation and Management of Pancreatic Neuroendocrine Tumors; State-of-the-Art Imaging of Pancreatic Neuroendocrine Tumors; Surgical Approaches to Pancreatic Neuroendocrine Tumors; and Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.

Gynecologic malignancies, especially endometrial and ovarian cancers are among the most important and most severely affected by obesity. This volume of Energy Balance and Cancer, written by the world's leading experts in this field, is arranged to provide a transdisciplinary assessment of the pertinent issues, results of relevant research on mechanisms, and control, strategies for dealing with affected patients and improving outcomes and future research needs. The volume comprehensively covers the epidemiology linking obesity to endometrial and ovarian cancer as well as the public awareness of this critical problem. Subsequent chapters explain biologic aspects of linkages between energy balance and gynecologic malignancies. The volume further outlines strategies to disrupt the linkage between obesity and gynecologic malignancies and concludes with a series of chapters focused on management strategies for obese patients with gynecologic malignancies. This volume provides a valuable resource for all physicians, scientists and other transdisciplinary investigators and practitioners interested and involved in energy balance and cancer. It should be a particularly useful guide to optimize outcomes for all practitioners dealing with patients with gynecologic malignancies challenged by energy balance issues. Moreover, it should serve as a useful guide to students and investigators interested in conducting further research on defining and disrupting the important linkage between energy balance and gynecologic malignancies.

This book is a compilation of past and recent knowledge in the field of emerging drug resistance. The book covers major aspects of drug resistance in bacteria, fungi, malaria, and cancer.Human survival on earth is constantly threatened by disease and syndrome. From the early days, the aim of research in medicine was to find therapeutic agents that can improve the quality of human life. Although humans are dependent on natural compounds from early days their dependence of drugs increased excessively in last century. The advances in chemistry and biology have helped researchers to identify the drugs that have improved treatment of many diseases. The primary factor for treatment of these diseases is dependent on the efficacy of drugs available. The development of resistance to these drugs is one of the major hindrances. Although there are number of books available on this topic, "drug resistance" biology across kingdoms has never been discussed in a coherent way.

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Michael Sand gives the reader an overview of current techniques in expression profiling of miRNAs and their maturation machinery in the skin. This book is a postdoctoral thesis on miRNAs in cutaneous malignant melanoma and non-melanoma skin cancer with a focus on the miRNA processing machinery and miRNA expression profiling. The research presented in this book was performed in the Dermatologic Surgery Section at the Department of Dermatology, Venereology and Allergology of the Ruhr-University Bochum, Germany and gives the reader an overview of current techniques in expression profiling of miRNAs and their maturation machinery in the skin.

There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009. A book focusing on these cancers was timely, with emergent sophistication in diagnosis increasingly impacting clinical decision-making. However, five years later, the need for an updated book on this topic is even stronger as oncologists recognize opportunities to impact the outcome on women that are increasingly diagnosed with these malignancies. Uterine Cancer: Screening, Diagnosis, and Treatment, Second Edition, part of the Current Clinical Oncology series, enhances the awareness on this somewhat neglected area of therapeutics, helping to integrate targeted therapies into the management of women with uterine cancer. Written by experts in the field in a highly practical and comprehensive manner, it is a must-have for all gynecological residents and fellows, as well as gynecological oncologists, medical oncologists, radiation oncologists, and family practice doctors who wish to provide their patients with the best possible care.

Retinoids have received considerable attention in recent years and due cognizance has been given to their versatility as biological response modifiers, as evidenced by the virtually explosive growth of literature in this field in the past few years. This volume has been designed to give a current state-of-the-art picture of retinoids. The perceived potential of retinoids in the treatment of certain disease stated has initiated attempts at identifying and synthesizing new retinoid derivatives with definable and selective effects on aberrant biological phenomena. Appropriately, therefore, we begin with the chemistry of retinoids and their derivatives together with discussions of their biological activity. Major advances have been made in understanding the mechanisms by which retinoids modulate physiological and phenotypic traits of cells. The transduction of retinoid signaling by the mediation of nuclear receptors of the steroid/thyroid receptor superfamily has now been studied extensively and the cloning and defining the characteristics of these receptors has been a focus of discussion in this volume. Retinoids also markedly modulate the transduction of extracellular signals such as those imparted by growth factors and hormones, and thus actively influence and control cellular proliferative patterns. Retinoids can alter epidermal growth factor receptor expression (Kawaguchi et al., 1994), responsiveness to thyroid hormone (Esfandiari et al., 1994; Pallet et al., 1994), inhibit the proliferative responses of hematopoietic progenitor cells to granulocyte colony stimulating factor (Smeland et al., 1994), and modulate secretion on interleukins by leukaemic cells (Balitrand et al., 1994), among other things. This has obvious implications for pharmacological manipulation of deregulated growth (Dickens and Colletta, 1993; Mulshine et al., 1993). Apoptosis is another component in the regulation of growth control. Apoptotic cell death is influenced by several agents and retinoids may function by interfering with apoptotic pathways of regulation of growth control and quite legitimately, therefore, the importance of this aspect of retinoid function has been duly recognized here.

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.

In 1950, a diagnosis of cancer was all but a death sentence. Mortality rates only got worse, and as late as 1986, an article in the New England Journal of Medicine lamented: We are losing the war against cancer." Cancer is one of humankind's oldest and most persistent enemies it has been called the existential disease.But we are now entering a new, and more positive, phase in this long campaign. While cancer has not been cured,and a cure may elude us for a long time yet,there has been a revolution in our understanding of its nature. Years of brilliant science have revealed how this individualistic disease seizes control of the foundations of life,our genes,and produces guerrilla cells that can attack and elude treatments. Armed with those insights, scientists have been developing more effective weapons and producing better outcomes for patients. Paul A. Marks, MD, has been a leader in these efforts to finally control this devastating disease.Marks helped establish the strategy for the war on cancer" in 1971 as a researcher and member of President Nixon's cancer panel. As the president and chief executive officer for nineteen years at the world's pre-eminent cancer hospital, the Memorial Sloan-Kettering Cancer centre, he was instrumental in ending the years of futility. He also developed better therapies that promise a new era of cancer containment. Some cancers, like childhood leukemia and non-Hodgkin's lymphoma, that were once deadly conditions, are now survivable,even curable. New steps in prevention and early diagnosis are giving patients even more hope. On the Cancer Frontier is Marks' account of the transformation in our understanding of cancer and why there is growing optimism in our ability to stop it.